Table 1.
Respondent and Non-respondent Characteristics
| Characteristics | Non-respondents, n (%) | Respondents, n (% |
|---|---|---|
| Response Rate | 203 | 68 |
| Respondent (complete) | – | 56 (55) |
| Respondent (incomplete) | – | 12 (12) |
| Not interested respondent | – | 33 (32) |
| Company Size | ||
| SME | 149 (73) | 44 (65) |
| Large company | 54 (27) | 24 (35) |
| Geography | ||
| United Kingdom | 36 (18) | 16 (24) |
| Germany | 33 (16) | 11 (16) |
| United States | 28 (14) | 5 (7) |
| France | 23 (11) | 7 (10) |
| The Netherlands | 16 (8) | 8 (12) |
| Other (Europe) | 64 (32) | 19 (30) |
| Other (rest of the world) | 3 (1) | 2 (3) |
| ATMP Type (Total) | ||
| GTMPs | 80 (40) | 31 (46) |
| Cell-based medicinal products | 121 (59) | 36 (53) |
| Combined ATMPs | 2 (1) | 1 (1) |
| No. of ATMPs in Development | ||
| 1 | 89 (44) | 33 (49) |
| >1 | 114 (56) | 35 (51) |
CTMP, cell therapy medicinal product; GTMP, gene therapy medicinal product; SME, small- and medium-sized enterprise (1–249 employees).22